0.4946

9.23% -0.0503

After Hours: .51 0.0154 +3.11%

Verrica Pharmaceuticals Inc (VRCA)

Overview News Price History Option Chain Financials Discussions Forecast

Verrica Pharmaceuticals Inc stock is traded at $0.4946, with a volume of 227.01K. It is down -9.23% in the last 24 hours and up +6.55% over the past month. Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Previous Close:

$0.5449

Open:

$0.5334

24h Volume:

227.01K

Relative Volume:

0.61

Market Cap:

$45.75M

Revenue:

$5.12M

Net Income/Loss:

$-67.00M

P/E Ratio:

-0.3365

EPS:

-1.47

Net Cash Flow:

$-38.94M

1W Performance:

-19.14%

1M Performance:

+6.55%

6M Performance:

-61.36%

1Y Performance:

-94.06%

1-Day Range:

$0.4939

$0.5334

1-Week Range:

$0.49

$0.6236

52-Week Range:

$0.3816

$9.36

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name

Verrica Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

484-453-3300

Address

10 NORTH HIGH STREET, WEST CHESTER, PA

Employee

Twitter

Next Earnings Date

2025-03-11

Latest SEC Filings

VRCA's Discussions on Twitter

Compare VRCA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRCA Verrica Pharmaceuticals Inc	0.4946	57.34M	5.12M	-67.00M	-38.94M	-1.47
ONC Beone Medicines Ltd Adr	245.58	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	64.44B	14.09B	4.50B	2.96B	39.28

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy
Mar-22-23	Initiated	Jefferies	Buy
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-21	Initiated	RBC Capital Mkts	Outperform
Dec-24-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy
Jun-24-20	Initiated	Northland Capital	Outperform
Mar-24-20	Initiated	Needham	Buy
Feb-21-19	Initiated	H.C. Wainwright	Buy

View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

02:10 AM

Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN

02:10 AM

May 28, 2025

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - GlobeNewswire

May 28, 2025

Verrica Pharmaceuticals CEO Reveals Dermatology Pipeline Updates at Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 25, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen - Defense World

May 25, 2025

Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Target Price at $8.00 - Defense World

May 25, 2025

May 24, 2025

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline - MSN

May 24, 2025

May 22, 2025

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN

May 22, 2025

May 21, 2025

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail

May 21, 2025

May 20, 2025

Verrica Pharmaceuticals’ SWOT analysis: stock faces cash crunch amid YCANTH growth - Investing.com Canada

May 20, 2025

Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World

May 16, 2025

May 15, 2025

Verrica signals sustainable growth trajectory as YCANTH revenues surpass $3M and Phase 3 milestone looms - MSN

May 15, 2025

May 14, 2025

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update - MSN

May 14, 2025

Verrica Pharmaceuticals (VRCA) Sees Q1 Revenue Growth Driven by YCANTH - GuruFocus

May 14, 2025

Verrica Pharmaceuticals (VRCA) Receives Hold Rating from Needham - GuruFocus

May 14, 2025